Journal Article

Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trial

Grootaert, Veerle, Huis in ‘t Veld, Diana, Van Wynsberge, Glenn, Buyle, Franky, De Cock, Pieter, Van Praet, Jens, Colman, Roos, Moors, Ine, Somers, Annemie

2024

Overview

Background Vancomycin is a commonly prescribed antibiotic to treat gram-positive infections. The efficacy of vancomycin is known to be directly related to the pharmacokinetic/pharmacodynamic (PK/PD) index of the area under the concentration-time curve (AUC) divided by the minimal inhibitory concentration (MIC) of the pathogen. However, in most countries, steady-state plasma concentrations are used as a surrogate parameter of target AUC/MIC, but this practice has some drawbacks. Hence, direct AUC-guided monitoring of vancomycin using model-informed precision dosing (MIPD) tools has been proposed for earlier attainment of target concentrations and reducing vancomycin-related nephrotoxicity. However, solid scientific evidence for these benefits in clinical practice is still lacking. This randomized controlled trial (RCT) aims to investigate the clinical utility of MIPD dosing of vancomycin administered via continuous infusion in hospitalized adults. Methods Participants from 11 wards at two Belgian hospitals are randomly allocated to the intervention group or the standard-of-care comparator group. In the intervention group, clinical pharmacists perform dose calculations using CE-labeled MIPD software and target an AUC24h of 400 to 600 mg × h/L, whereas patients in the comparator group receive standard-of-care dosing and monitoring according to the institutional guidelines. The primary endpoint is the proportion of patients reaching the target AUC24h/MIC of 400–600 between 48 and 72 h after start of vancomycin treatment. Secondary endpoints are the proportion of patients with (worsening) acute kidney injury (AKI) during and until 48 h after stop of vancomycin treatment, the proportion of patients reaching target AUC24h/MIC of 400–600 between 72 and 96 h after start of vancomycin treatment, and the proportion of time within the target AUC24h/MIC of 400–600. Discussion This trial will clarify the propagated benefits and provide new insights into how to optimally monitor vancomycin treatment. Trial registration EudraCT number: 2021-003670-31. Registered June 28, 2021. ClinicalTrials.gov identifier: NCT05535075. Registered September 10, 2022. Protocol version 3, protocol date: April 21, 2023.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adult / Anti-Bacterial Agents / Antibiotic / Antibiotics / Area Under Curve / Biomedicine / Clinical trials / Continuous infusion / Creatinine / Dosage and administration / Drug dosages / Drug stores / Drug utilization / Health Facilities / Health Sciences / Hematology / Hospitals / Humans / Hypotheses / Infectious diseases / Informed consent / Internal medicine / Kidneys / Medical research / Medicine / Medicine & Public Health / Methods / Microbial Sensitivity Tests / Model-informed precision dosing / Objectives / Pathogens / Patients / Pharmacokinetics / Randomized controlled trial / Staphylococcus infections / Statistics for Life Sciences / Study Protocol / Testing / Therapeutic drug monitoring / Vancomycin / Vancomycin - adverse effects